Literature DB >> 3664159

Anticardiolipin antibodies in rheumatoid arthritis.

A Keane1, R Woods, V Dowding, D Roden, C Barry.   

Abstract

Anticardiolipin antibody (ACA) was present in the sera of 49% of 90 consecutive patients with rheumatoid arthritis (RA). The ACA was absent in 30 control patients with osteoarthritis. C-reactive protein levels equal to or exceeding 7 mg/dl were found in 10 patients all of whom were ACA positive. ACA was present in a larger proportion of rheumatoid factor (RF) positive than of RF negative patients. Male sex and extra-articular manifestations of RA were both more common in ACA positive than ACA negative patients. In the ACA positive group the lupus anticoagulant and VDRL tests were negative. However, a small number of patients had evidence of vascular events.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3664159     DOI: 10.1093/rheumatology/26.5.346

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  10 in total

1.  Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.

Authors:  T Jonsdottir; J Forslid; A van Vollenhoven; A Harju; S Brannemark; L Klareskog; R F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2004-04-05       Impact factor: 19.103

Review 2.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

3.  Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies.

Authors:  R A Fields; W L Sibbitt; H Toubbeh; A D Bankhurst
Journal:  Ann Rheum Dis       Date:  1990-02       Impact factor: 19.103

4.  Antiphospholipid antibodies in mixed connective tissue disease.

Authors:  A Doria; A Ruffatti; A Calligaro; T Del Ross; A Ghirardello; P De Zambiasi; P Gambari
Journal:  Clin Rheumatol       Date:  1992-03       Impact factor: 2.980

Review 5.  The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis.

Authors:  Ewa Olech; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

6.  Anticardiolipin antibodies in patients with rheumatoid arthritis.

Authors:  A J de Brum-Fernandes; W Cossermelli-Messina; C Bueno; M Barreto Santiago; W Weidebach; W Cossermelli; R M de Oliveira
Journal:  Clin Rheumatol       Date:  1989-12       Impact factor: 2.980

7.  Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies.

Authors:  M Blank; J Cohen; V Toder; Y Shoenfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

8.  Antibodies to cardiolipin and intermediate filaments: a study of autoimmunity in rheumatoid arthritis.

Authors:  R Jacobs; M G Butler; D L Scott
Journal:  Clin Rheumatol       Date:  1990-12       Impact factor: 2.980

9.  Recurrent thrombosis and anticardiolipin antibodies associated with adenocarcinoma of the lung.

Authors:  M N Shaukat; P Hughes
Journal:  Postgrad Med J       Date:  1990-04       Impact factor: 2.401

10.  Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.

Authors:  Fabiola Atzeni; Piercarlo Sarzi-Puttini; Donata Dell' Acqua; Simona de Portu; Germana Cecchini; Carola Cruini; Mario Carrabba; Pier Luigi Meroni
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.